Olink and gut microbial metabolomics reveal new biomarkers for the prediction and diagnosis of PMOP
Journal of Bone and Mineral Metabolism, 2024
Wu R., Wu J., Jin H., Ma H., Huang H., Xu W., Sun S., Liu X., Dong K., Xie Y., Zeng J., Wang F.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Other Diseases & Syndromes | Patient Stratification | Plasma | O Olink Target 96 |
Abstract
lntroduction
Postmenopausal osteoporosis (PMOP) can cause postmenopausal women to experience pain and interference. Identifying and exploring potential early diagnostic biomarkers of PMOP is of substantial clinical value and social significance. This study aimed to screen for potential novel diagnostic biomarkers of PMOP through a multiomics approach, providing new directions and ideas for the early prevention and treatment of this disease.
Materials and Methods
Fifteen postmenopausal women with osteoporosis and 12 without were recruited. Clinical information was collected, and various clinical biochemical parameters were tested. Plasma and fecal samples were collected and analyzed using Olink proteomics and gut microbial metabolomics.
Results
The functions of the differentially abundant metabolites were mainly related to autophagy and arginine and proline metabolism and were involved in immunoinflammatory metabolic processes. Olink showed significant differences in the expression of seven inflammation-related proteins between the two groups.
Conclusion
We demonstrated that metabolic differences between PMOP patients and healthy controls were associated with inflammatory responses and found seven proteins with significant differences. Among these proteins, CDCP1, IL10, and IL-1alpha combined with clinical indicators had high discriminant efficiency in identifying PMOP. This is also the first study to demonstrate noteworthy changes in CDCP1 levels in patients with PMOP.